<DOC>
	<DOCNO>NCT01313611</DOCNO>
	<brief_summary>The objective study evaluate complete response rate short induction treatment rituximab ( 375mg/m2 ) bendamustine ( 90mg/m2 ) In Elderly ( ≥ 60 year old ) patient untreated Follicular lymphoma , intermediate high FLIPI score without high tumor burden . This short induction follow rituximab ( 375mg/m2 ) maintenance/ Induction schedule : Rituximab+Bendamustine Day 1 , Bendamustine Day 2 , Rituximab Day 8 , Rituximab Day 15 , rituximab day 22 , Bendamustine Day 29 , Bendamustine Day 30 Maintenance schedule : 12 infusion rituximab , 8 week</brief_summary>
	<brief_title>BRIEF Bendamustine Rituximab In Elderly Follicular</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histologically confirm follicular lymphoma CD20+ , grade except grade 3b lymph node biopsy perform within 6 month study entry material available central review A minimal initial immunology require , include : CD20 , bcl2 , CD10 CD5 Age must ≥ 60 year Patients previously treat Patients intermediate high risk FLIPI score require 2 follow adverse prognostic factor : 1 . Age &gt; 60 an 2 . Ann Arbor Stage ( IIIIV vs. III ) 3 . Hemoglobin level ( &lt; 12g/dL vs. ≥ 12 g/dL ) 4 . Number nodal area ( &lt; 5 vs. ≥ 5 ) ( Note : LDH consider adverse prognostic factor study since consider high tumor burden GELF criterion ) Low burden disease study entry accord GELF criterion Patients least one measurable site disease : patient blood marrow splenic infiltration exclude Performance status ≤ 2 ECOG scale Adequate hematological function ( unless abnormality relate lymphoma infiltration bone marrow ) include : Hemoglobin ≥ 8.0 g/dL ( 5.0 mmol/L ) Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Adequate renal function : calculated creatinine clearance &gt; 50 ml/min ( accord MDRD method ) unless abnormality relate lymphoma Adequate hepatic function : Total bilirubin &lt; 2.0 mg/dl ( 34 µmol/L ) , AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 x upper limit normal unless abnormality relate lymphoma Adequate cardiac function : LEVF ≥ 50 % calculated echocardiography scintigraphy Having previously sign write informed consent Other histological type lymphoma follicular lymphoma Grade 3b follicular lymphoma Patients previously watch wait since 6 month diagnosis Patients previously treat lymphoma , except splenectomy Patients low FLIPI score ( 0 1 adverse prognostic factor consider elevated LDH ) Bulky disease study entry accord GELF criterion Presence history CNS disease ( either CNS lymphoma lymphomatous meningitis ) Patients prior concomitant malignancy except nonmelanoma skin cancer adequately treat situ cervical cancer previous cancer CR without treatment last 5 year Positive HIV , HBV ( antiHBc positivity ) HCV serologies inclusion Poor Performance status &gt; 2 ECOG scale Known contraindication study product Serious underlie medical condition , could impair ability patient participate trial ( e.g . ongoing infection , uncontrolled diabetes mellitus , gastric ulcer , active autoimmune disease ) . Any coexist medical psychological condition preclude participation study compromise ability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>